Suppr超能文献

强化他汀治疗对有症状颅内动脉狭窄的影响。

The Effect of Intensive Statin Therapy on Symptomatic Intracranial Arterial Stenosis.

作者信息

Zhou Peiyang, Cao Zhihua, Wang Pu, Liu Guangzhi, Yao Xuan, Wang Puqing, Li Guang, Zhang Guibin, Gao Ping

机构信息

Dept. of Neurology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China.

Dept. of Radiology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China.

出版信息

Iran J Public Health. 2018 Feb;47(2):231-236.

Abstract

BACKGROUND

The aim of this study was to observe the effect of intensive statin therapy on symptomatic intracranial arterial stenosis.

METHODS

overall, 120 patients with symptomatic intracranial arterial stenosis were admitted to the Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China from January 2010 to May 2013. They were randomly divided into three groups and were given different doses of atorvastatin orally for 1 year or more, and followed up for 12 months. The three groups were assessed for clinical end-point event rates and changes in cerebral blood flow value before and after treatment to assess the effectiveness of intensive statin therapy.

RESULTS

The incidence rates of end-point cerebrovascular events in the low-dose group (10 mg/d), the general-dose group (20 mg/d) and the intensive treatment group (40 mg/d) were 26.3%, 13.5% and 5.4% respectively during the 12-month follow-up after treatment. There was a significant difference between the low dose group and the intensive treatment group (<0.05). The relative cerebral blood flow and relative cerebral blood volume of the three groups were significantly higher than those before treatment (<0.05), and the relative time to peak for the intensive treatment group was shorter than that before treatment (<0.001).

CONCLUSION

Atorvastatin at 40 mg/d has a significant advantage compared with atorvastatin at 20 mg/d and 10 mg/d in reducing cerebrovascular events and improving cerebral blood flow.

摘要

背景

本研究旨在观察强化他汀类药物治疗对症状性颅内动脉狭窄的影响。

方法

2010年1月至2013年5月,共有120例症状性颅内动脉狭窄患者入住中国湖北省襄阳市湖北医药学院附属襄阳市第一人民医院。他们被随机分为三组,口服不同剂量阿托伐他汀1年以上,并随访12个月。评估三组的临床终点事件发生率以及治疗前后脑血流值的变化,以评估强化他汀类药物治疗的有效性。

结果

治疗后12个月随访期间,低剂量组(10毫克/天)、常规剂量组(20毫克/天)和强化治疗组(40毫克/天)的终点脑血管事件发生率分别为26.3%、13.5%和5.4%。低剂量组与强化治疗组之间存在显著差异(<0.05)。三组的相对脑血流量和相对脑血容量均显著高于治疗前(<0.05),强化治疗组的相对达峰时间短于治疗前(<0.001)。

结论

与20毫克/天和10毫克/天的阿托伐他汀相比,40毫克/天的阿托伐他汀在降低脑血管事件和改善脑血流方面具有显著优势。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验